Chris Lehman / Collabrity, Inc.

Corporate partnering expertise for emergent life science companies

MISSION

I assist clients by providing expert negotiation advice and leadership in order to help execute their mission-critical business development transactions.

SUMMARY

• corporate partnering

• intellectual property licensing
• strategic planning for partnering

• extensive business development experience in the biopharmaceutical industry
• an exceptional knowledge base
• a global network among senior executives, investors and scientists

EDUCATION

1993 M.B.A. with Honors, University of California at Berkeley, Haas School of Business
1983 B.A. cum laude in History, Yale University, New Haven, CT

CLIENTS

• Angiogenix prepared financial plan and presentation for Series D financing
• Applied Genetic Technologies Corporation (AGTC) a series A, AAV gene therapy company funded by Interwest, Skyline, MedImmune Ventures and InterSouth. Head of BD role. Led efforts to negotiate and close corporate partnership with Genzyme. Other deals completed: MedImmune, U. Alabama.

• Aryx performed valuation of GI asset subsequently licensed to P&G Pharma (see PR below)
• Eli Lilly, Chorus division Developed business case for proposed spin-out of company
• Enterprise Partners Venture Capital Delivered comprehensive valuation of portfolio company Celladon’s gene therapy for heart failure
• Exelixis Assessed combinatorial chemistry partnering opportunity

• MaxCyte Conducted out-licensing efforts for novel oncology cell therapy

• NeurAxon Prepared CEO for board presentation evaluating deal landscape for a novel CNS therapy
• PDxRx a startup specialty pediatric pharma company that has raised $1 million in angel funding. Head of BD and CFO. Negotiated key terms agreements on 3 product in-license deals. Helped give 2 dozen presentations to top-tier VC firms. Acted as the company’s CFO, developing and customizing the company’s financial model for investor communications.

• Synamem Prepared business plan for private investor (William Rutter, PhD) financing

CLIENT PROFILE

• small to mid-size biopharmaceutical companies
• with strong individual investor or venture capital support

• without internal BD staff
• that intend to attract the partnering interests of large pharmaceutical or biotech companies and

• require senior-level business development expertise to achieve their partnering goals.

I am typically engaged by senior management or directors or venture capital investors in the company to supply or augment skills that are internally underrepresented or simply overextended. I can provide the skills needed to develop databases of potential partners prioritized by client criteria, to prepare business cases establishing the value of the deal and to execute negotiations on advantageous terms. After helping to establish interest among potential counterparties, my primary focus is on preparing for and running transactions from the advent of discussions where a serious interest exists on both sides to reach term sheet agreement and then through to deal execution.

REASONS FOR CEOs TO OUTSOURCE BUSINESS DEVELOPMENT CAMPAIGNS

PRESS RELEASES

JULY, 2006: ARYX AND P&G PHARMA FORM GI PRODUCT ALLIANCE

I advised ARYX on this transaction

DECEMBER, 2004: GENZYME, AGTC ANNOUNCE GENE THERAPY COLLABORATION

I advised AGTC on this transaction

JANUARY, 2002: GENENCOR, SEATTLE GENETICS … TARGETED CANCER THERAPIES

I led this transaction for Genencor

____________________________

QUALIFICATIONS

Detailed resume, deal sheet, and references available upon request

CONTACT

Chris Lehman

Collabrity, Inc.
510.520.4637 Tel
510.280.9320 Fax

chrislehmanbd@yahoo.com

Collabrity website: www.collabrity.biz

Pacific Daylight Time / Oakland, California

Each month I donate a portion of my client receipts to The CALICO Center and acknowledge them in my gift. CALICO has re-engineered an essential social service, becoming a national model in its field. I encourage others to learn about and support CALICO’s innovative work.